Clinical Trial News and Research

RSS

Kidney Week 2026 features late-breaking clinical trials in kidney care

The American Society of Nephrology, has selected the following late breaking clinical trials to be presented in-person at Kidney Week 2026 October 22–25.

24 Oct 2026

Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy

Results from a clinical trial have revealed nearly one third (29.2 percent) of patients with advanced melanoma saw their tumors disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, pembrolizumab, as a first-line treatment.

24 Oct 2026

Novel immunosuppressant improves kidney function and quality of life after transplantation

The Phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant.

23 Oct 2026

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.

23 Oct 2026

Digital tools and phone coaching boost cancer genetic testing uptake

About 10% of cancers are linked to an inherited genetic variant, but as few as 1 in 15 cancer patients eligible for genetic testing complete it.

23 Oct 2026

Targeted drug extends survival across diverse pancreatic cancer patient groups

A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation.

23 Oct 2026

EEG monitoring offers new way to detect cybersickness

For years, developers of virtual reality (VR) and augmented reality (AR) technologies have worked to address an unwanted side effect many users experience: cybersickness, a type of motion sickness triggered by moving digital content.

23 Oct 2026

Gut microbiome differences may explain varied sleep responses to hydrogen supplementation

Hiroshima University researchers investigated the effects of hydrogen supplementation on sleep quality in healthy human volunteers.

23 Oct 2026

Decipher tissue-based molecular test helps personalize high-risk prostate cancer treatment

Prostate cancer is the most common cancer in men – in 2013, it affected more than one million men across the world.

23 Oct 2026

Dual-targeted therapy shows promise against metastatic triple-negative breast cancer

A new preclinical study suggests that attacking triple-negative breast cancer (TNBC) in two ways at once can kill cancer cells, slow tumor growth and limit the cancer's spread. Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) developed the approach.

23 Oct 2026

Potassium binder helps dialysis patients manage dietary restrictions

Dietary potassium restriction is important for managing hyperkalemia, or high blood potassium levels, in individuals on maintenance hemodialysis, but it imposes a substantial day-to-day burden.

22 Oct 2026

Fruits and vegetables may be a better option to improve kidney disease outcomes

In people with chronic kidney disease (CKD), oral sodium bicarbonate is a standard treatment for metabolic acidosis (too much acid buildup in the body), but results from a recent clinical trial indicate that dietary acid reduction with base producing fruits and vegetables may be a better option.

22 Oct 2026

Clinical trial establishes effective HIV dosing regimen for full-term newborns

An international study conducted through the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network including researchers at the University of California San Diego helped inform the U.S. Food and Drug Administration's (FDA) recent approval of dolutegravir, a second-generation integrase inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in newborns from birth.

22 Oct 2026

Emotion management helps teens maintain weight loss after treatment

Researchers from University of California San Diego have found that adding emotion management skills to family-based behavioral weight management may help adolescents maintain weight loss after treatment ends.

22 Oct 2026

FDA grants accelerated approval to groundbreaking rectal cancer immunotherapy

A groundbreaking immunotherapy treatment for rectal cancer, developed through pioneering research at Memorial Sloan Kettering Cancer Center (MSK) with critical early-stage funding from Swim Across America, has received accelerated approval from the U.S. Food and Drug Administration (FDA).

22 Oct 2026

New national trial platform aims to accelerate Alzheimer's disease prevention

Researchers from the University of California San Diego will join a collaboration as part of a federal award of up to $41 million to launch a national effort aimed at accelerating the search for treatments that could prevent or slow Alzheimer's disease.

22 Oct 2026

Study identifies blood proteins associated with aggressive prostate cancer risk

Proteins linked to the immune system, cell adhesion, blood vessel formation and known prostate cancer genes, were associated with the future risk of developing prostate cancer, including aggressive disease, in a new study led by researchers at Oxford Population Health.

21 Oct 2026

ECOG-ACRIN opens trial testing ivonescimab for aggressive bile duct cancer

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it will open a randomized, registration-enabling phase 2/3 clinical trial to evaluate ivonescimab combined with chemotherapy as first-line treatment for patients with advanced biliary tract cancer (BTC).

21 Oct 2026

Oxaloacetate supplement may help reduce chemo brain in breast cancer survivors

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that a nutritional supplement containing oxaloacetate, a molecule naturally found in the body that helps cells produce energy, may help improve cognitive function and reduce the fatigue experienced by some breast cancer survivors following treatment.

21 Oct 2026

Qureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands

Qureight, an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced it has been selected by Celea Therapeutics as the imaging CRO to support Celea’s Phase 3 SURPASS-IPF clinical trial.

From Qureight 21 Oct 2026